Heartbeam stock rating held at Neutral by H.C. Wainwright on FDA news

H.C. Wainwright maintained a neutral stock rating for Heartbeam Inc. (NASDAQ:BEAT) after the company received FDA Breakthrough Device designation for its HeartBeam System. The rating remains despite the stock's impressive 78% increase over the past week, which pushed the price to $0.65. However, the company's market capitalization is still relatively small at $36.86 million.

The FDA granted the designation for the system, which aims to detect potential heart attacks at home. This designation is backed by data from the 134-patient ALIGN-ACS pilot study, demonstrating the 3D ECG technology's capabilities. The technology captures the heart's electrical signals in three non-coplanar dimensions, allowing physicians to evaluate signs of myocardial infarction when symptoms begin.

HeartBeam's system offers access to clinical-grade ECG data outside the hospital, and the company is developing its heart attack assessment capability on the same 3D ECG platform used for its FDA-cleared arrhythmia product. The Breakthrough Device designation enables the company to pursue an expedited Medicare coverage pathway, as heart attack detection is the company's top priority.

The recent designation is expected to accelerate both clinical and regulatory development. However, HeartBeam's second-quarter earnings report revealed a significant earnings miss, with an EPS of -$1.10, falling short of analyst forecasts by $1.01 per share. This unexpected loss occurred despite improvements in operating trends.

Additionally, HeartBeam entered into an at-the-market (ATM) equity offering agreement with Titan Partners Securities LLC. This agreement allows the company to sell up to $25 million of its common stock through the Nasdaq Capital Market under the company's shelf registration statement. These recent developments highlight HeartBeam's ongoing financial and strategic activities.